Engineered Protein ACT-101 Shows Potential in Mouse Model of Colitis, Study Shows

Engineered Protein ACT-101 Shows Potential in Mouse Model of Colitis, Study Shows
Researchers have found that Alpha Cancer Technologies' ACT-101, an engineered protein similar to the human alpha fetoprotein (hAFP), can protect mice from developing bowel inflammation. This finding resulted from a preclinical study that was the subject of a poster presentation titled, “Anti-inflammatory properties of recombinant human alpha-fetoprotein (rhAFP) in the model of TNBS-induced colitis,” presented at the World Congress of Gastroenterology 2017, held in collaboration with The American College of Gastroenterology in Orlando, Florida. The protein hAFP is produced only by embryos during fetal development. It has the ability to regulate the immune responses of the mother, protecting the embryo from harmful attacks from the mother’s immune cells. During pregnancy, women with autoimmune disorders, including myasthenia gravis and multiple sclerosis, can present signs of disease remission, an effect that's been associated with the rise and fall of hAFP levels. This observation suggests the protein may hold potential as an immune modulator for autoimmune illnesses. Alpha Cancer Technologies developed a recombinant protein of hAFP called ACT-101 for the treatment of inflammatory bowel disease (IBD), myasthenia gravis, and other inflammatory diseases. A previous clinical study tested the therapeutic effects of hAFP compared to a placebo in 78 patients with IBD. This study showed that daily administration of hAFP for 30 days could significantly reduce disease symptoms, colonic inflammation and ulcerative lesions. In addition, Phase 1 and 2 clinical studies in other diseases or disorders involving more than
Subscribe or to access all post and page content.